Ashley B Grossman

Author PubWeight™ 177.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cushing's syndrome. Lancet 2006 5.19
2 Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008 4.68
3 The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002 3.43
4 Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007 3.25
5 AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 2011 3.14
6 The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004 2.88
7 The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2005 2.80
8 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007 2.10
9 Ghrelin--a hormone with multiple functions. Front Neuroendocrinol 2004 1.88
10 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005 1.83
11 Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005 1.79
12 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008 1.78
13 Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol 2012 1.73
14 The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003 1.61
15 Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2003 1.60
16 Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) 2007 1.50
17 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010 1.49
18 The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008 1.49
19 Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab 2003 1.47
20 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008 1.42
21 Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 2013 1.39
22 Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) 2008 1.32
23 Rathke's cleft cysts. Clin Endocrinol (Oxf) 2012 1.32
24 CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol 2004 1.29
25 Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006 1.29
26 Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 2010 1.26
27 Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008 1.25
28 Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 2010 1.22
29 The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007 1.19
30 Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol 2003 1.19
31 Lymphoma metastasizing to the pituitary: an unusual presentation of a treatable disease. Pituitary 2005 1.18
32 The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010 1.18
33 Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med 2013 1.15
34 Work-up and management of paediatric Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2008 1.15
35 Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007 1.15
36 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2008 1.15
37 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009 1.15
38 Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) 2003 1.14
39 Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol 2009 1.12
40 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2007 1.11
41 AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008 1.11
42 Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 2009 1.09
43 Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005 1.09
44 Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol 2004 1.07
45 Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004 1.06
46 Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011 1.05
47 Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol 2012 1.05
48 Endocrine manifestations in Langerhans cell histiocytosis. Trends Endocrinol Metab 2007 1.05
49 Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009 1.04
50 Adrenal incidentalomas: 'the rule of four'. Clin Med 2008 1.04
51 Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab 2007 1.02
52 Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005 1.02
53 Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 2010 1.01
54 The role of AMP-activated protein kinase in obesity. Front Horm Res 2008 1.01
55 Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 2005 1.00
56 Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008 1.00
57 Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer 2008 0.99
58 Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab 2007 0.99
59 Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. J Clin Endocrinol Metab 2006 0.98
60 Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 2012 0.98
61 Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 2012 0.98
62 ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014 0.97
63 Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006 0.97
64 The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009 0.97
65 The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol 2009 0.95
66 Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obesity (Silver Spring) 2009 0.94
67 Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) 2008 0.94
68 Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol 2011 0.94
69 Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab 2010 0.94
70 Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002 0.94
71 A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. J Clin Endocrinol Metab 2005 0.94
72 Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 2004 0.94
73 Mini-review: pheochromocytomas causing the ectopic ACTH syndrome. Endocrine 2012 0.93
74 Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 2013 0.92
75 The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004 0.92
76 Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine 2011 0.92
77 Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther 2010 0.92
78 Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol 2010 0.92
79 Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004 0.91
80 The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. Eur J Endocrinol 2009 0.91
81 CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics 2004 0.91
82 A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 2002 0.91
83 Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol 2012 0.90
84 Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab 2014 0.90
85 The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 2009 0.89
86 Advances in the management of paediatric Cushing's disease. Horm Res 2008 0.89
87 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2012 0.89
88 Whole-exome sequencing studies of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2013 0.89
89 The diagnosis and management of parasellar tumours of the pituitary. Endocr Relat Cancer 2008 0.88
90 Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 2002 0.88
91 Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol 2005 0.87
92 A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clin Endocrinol (Oxf) 2012 0.87
93 Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol 2013 0.87
94 Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf) 2013 0.87
95 Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab 2015 0.86
96 Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 2005 0.86
97 The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2007 0.86
98 Cyclins and their related proteins in pituitary tumourigenesis. Mol Cell Endocrinol 2010 0.86
99 Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res 2004 0.86
100 Is urinary free cortisol of value in the diagnosis of Cushing's syndrome? Curr Opin Endocrinol Diabetes Obes 2011 0.86
101 MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am J Physiol Endocrinol Metab 2012 0.86
102 Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol 2010 0.85
103 Ghrelin's role as a major regulator of appetite and its other functions in neuroendocrinology. Prog Brain Res 2010 0.85
104 Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin Ther Targets 2009 0.85
105 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006 0.85
106 Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1. Endocr Pract 2011 0.84
107 Specific electrocardiographic features associated with Cushing's disease. Clin Endocrinol (Oxf) 2011 0.84
108 Differential diagnosis of Cushing's syndrome. Arq Bras Endocrinol Metabol 2007 0.84
109 The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol 2005 0.84
110 The clinical significance of adrenal incidentalomas. Eur J Clin Invest 2011 0.83
111 PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 2006 0.83
112 ACTH and alpha-MSH inhibit leptin expression and secretion in 3T3-L1 adipocytes: model for a central-peripheral melanocortin-leptin pathway. Mol Cell Endocrinol 2003 0.83
113 Phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension. Hormones (Athens) 2009 0.83
114 Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin Endocrinol (Oxf) 2003 0.83
115 Differential diagnosis of adrenocorticotropic hormone-independent Cushing syndrome: role of adrenal venous sampling. Endocr Pract 2012 0.83
116 Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric Cushing's disease. Clin Endocrinol (Oxf) 2013 0.83
117 A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007 0.82
118 Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia. Nat Rev Endocrinol 2009 0.82
119 Role of regulatory factors in pituitary tumour formation. Front Horm Res 2004 0.82
120 Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones (Athens) 2012 0.82
121 Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice. Endocr J 2012 0.82
122 Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report. Endokrynol Pol 2008 0.82
123 The management of head-and-neck paragangliomas. Endocr Relat Cancer 2013 0.82
124 Mutational analysis of the adaptor protein 2 sigma subunit (AP2S1) gene: search for autosomal dominant hypocalcemia type 3 (ADH3). J Clin Endocrinol Metab 2014 0.81
125 Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. Stress 2012 0.81
126 Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary 2009 0.81
127 The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis. Endocr Pathol 2015 0.81
128 Novel insights in the diagnosis of Cushing's syndrome. Neuroendocrinology 2010 0.80
129 CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. J Endocrinol 2013 0.80
130 Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf) 2013 0.80
131 Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Mol Cell Endocrinol 2012 0.80
132 Carcinoid Heart Disease: From Pathophysiology to Treatment--'Something in the Way It Moves'. Neuroendocrinology 2015 0.80
133 Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol 2009 0.80
134 Confusing genes: a patient with MEN2A and Cushing's disease. Clin Endocrinol (Oxf) 2013 0.80
135 Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids. Clin Med 2011 0.79
136 Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf) 2009 0.79
137 Diagnosis and treatment of pediatric Cushing's disease. Pituitary 2007 0.79
138 Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Neuroendocrinology 2009 0.79
139 Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. Arq Bras Endocrinol Metabol 2007 0.79
140 Osteoporosis in Cushing's syndrome. Front Horm Res 2002 0.78
141 Secondary forms of polycystic ovary syndrome. Trends Endocrinol Metab 2004 0.78
142 The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary 2002 0.78
143 Protein western array analysis in human pituitary tumours: insights and limitations. Endocr Relat Cancer 2008 0.78
144 Imaging in Cushing's syndrome. Arq Bras Endocrinol Metabol 2007 0.78
145 A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004 0.78
146 The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Nucl Med Commun 2006 0.78
147 Imaging in covert ectopic ACTH secretion: a CT pictorial review. Eur Radiol 2009 0.78
148 Growth and growth hormone secretion in paediatric Cushing's disease. Hormones (Athens) 2006 0.77
149 Acromegaly: Beyond surgery. Indian J Endocrinol Metab 2013 0.77
150 Where metabolism meets oncogenesis: another false lead? Lancet Oncol 2010 0.77
151 Ectopic ACTH syndrome. Front Horm Res 2006 0.77
152 The pathology of pituitary adenomas from a clinical perspective. Front Biosci (Schol Ed) 2011 0.77
153 Pituitary tumors in 2010: a new therapeutic era for pituitary tumors. Nat Rev Endocrinol 2011 0.77
154 Treatment of advanced neuroendocrine tumours with the radiolabelled somatostatin analogue octreotide. Hormones (Athens) 2006 0.77
155 The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest 2011 0.76
156 Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG. Hormones (Athens) 2006 0.76
157 Pituitary-targeted medical therapy of Cushing's disease. Expert Opin Investig Drugs 2008 0.76
158 Medical therapy of Cushing's disease: where are we now? Front Horm Res 2010 0.76
159 Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 2014 0.76
160 Dynamic testing in Cushing's syndrome. Pituitary 2008 0.76
161 A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010 0.76
162 The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J 2013 0.76
163 Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours? Clin Endocrinol (Oxf) 2013 0.76
164 Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly? J Clin Endocrinol Metab 2013 0.76
165 Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J Clin Endocrinol Metab 2003 0.76
166 Emerging drugs for Cushing's disease. Expert Opin Emerg Drugs 2015 0.76
167 Diagnosing diabetes on admission hyperglycaemia. Heart 2011 0.75
168 The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors. Cancer Biol Ther 2008 0.75
169 The heme oxygenase-carbon monoxide pathway in the control of neuroendocrine function. Front Horm Res 2002 0.75
170 Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer. Lung Cancer 2009 0.75
171 Changes in the Epidemiology of Neuroendocrine Tumours. Neuroendocrinology 2015 0.75
172 Dandy-Walker malformation, papillary thyroid carcinoma, and SDHD-associated paraganglioma syndrome. J Clin Endocrinol Metab 2013 0.75
173 A thymic carcinoid tumour causing Zollinger-Ellison and Cushing's syndromes due to ectopic ACTH and gastrin secretion. Hormones (Athens) 2013 0.75
174 A case of hiccoughs. Clin Med 2011 0.75
175 Molecular pathways of human adrenocortical carcinoma - translating cell signalling knowledge into diagnostic and treatment options. Endokrynol Pol 2016 0.75
176 GnRH analogue use in postmenopausal hyperandrogenism: long-term remission. Endocrine 2012 0.75
177 Recurrent pituitary ependymoma: a complex clinical problem. Pituitary 2010 0.75
178 Diagnosis and treatment of Cushing's disease in children. Endocr Dev 2009 0.75
179 Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy. Neuroendocrinology 2017 0.75
180 Transsphenoidal pituitary surgery in the elderly is safe and effective. Br J Neurosurg 2013 0.75
181 Investigation for Paediatric Cushing's Syndrome Using Twenty-Four-Hour Urinary Free Cortisol Determination. Horm Res Paediatr 2016 0.75
182 Cancer in the thyroid is not always thyroid cancer. Hormones (Athens) 2006 0.75
183 Pituitary radiotherapy. Pituitary 2009 0.75
184 Examining the candidacy of ghrelin as a gene responsible for variation in adult stature in a United Kingdom population with type 2 diabetes. J Clin Endocrinol Metab 2007 0.75